Radius

Quote












anonymous said:
anyone look into this?
Click to expand...

Yes, had and F to F yesterday. Seems like an interesting start up with second PTH to market. Unfortunately looking to hire CSO reps to start. Can't understand the high share with limited revenues. Still Teva has generic form in about 18 months. Not real impressed with upper management. RR seems way over his head
 






anonymous said:
Yes, had and F to F yesterday. Seems like an interesting start up with second PTH to market. Unfortunately looking to hire CSO reps to start. Can't understand the high share with limited revenues. Still Teva has generic form in about 18 months. Not real impressed with upper management. RR seems way over his head
Click to expand...

Who is RR?
 




































anonymous said:
Sales director in east doing most of the interviews. My opinion only, but the business plan is to make shareholders a high return, not to make employees happy...#acadia
Click to expand...

You are saying this like there is something wrong with it. And CSO reps are better utilized for cases like these ecause when the company is acquired there is less overhead. They just turn the CSO reps off and they go away, it's beautiful actually
 












anonymous said:
You are saying this like there is something wrong with it. And CSO reps are better utilized for cases like these ecause when the company is acquired there is less overhead. They just turn the CSO reps off and they go away, it's beautiful actually
Click to expand...

This has been the subject of multiple meetings and conference calls. What is the area under the curve for CSO reps versus direct employees? If you were going against prolia and Forteo reps, you may want direct. But for a fast sale and increased net revenue, the CSO may be the way to go.but the stock is dropping, so as an investor, I am clueless. My preference for the business is CSO
 






anonymous said:
This has been the subject of multiple meetings and conference calls. What is the area under the curve for CSO reps versus direct employees? If you were going against prolia and Forteo reps, you may want direct. But for a fast sale and increased net revenue, the CSO may be the way to go.but the stock is dropping, so as an investor, I am clueless. My preference for the business is CSO
Click to expand...

I stock on the way to $18. Q3 earnings very unimpressive
 












research.... per financials

1/2 billion in the hole
FDA approval planned for 3.2017 assume delay
Forteo goes generic 2018
Radius price point...?
financials need to be greater than marginally profitable to maintain viability past 2018 and feed R&D for pipeline or look for acquisition.
Medicare pushing out of pocket cost to patients (not surprised if criteria is failure first prior to more expensive drug) as always in our industry.
bottom line you have to take risk to reap benefits or learn from failure to grow stronger....

Best of Luck ..
 






anonymous said:
research.... per financials

1/2 billion in the hole
FDA approval planned for 3.2017 assume delay
Forteo goes generic 2018
Radius price point...?
financials need to be greater than marginally profitable to maintain viability past 2018 and feed R&D for pipeline or look for acquisition.
Medicare pushing out of pocket cost to patients (not surprised if criteria is failure first prior to more expensive drug) as always in our industry.
bottom line you have to take risk to reap benefits or learn from failure to grow stronger....

Best of Luck ..
Click to expand...

All I had to do was look up the backgrounds of all RDs that have already been hired on LinkedIn. To me this is a SURE sign you are having difficulty getting qualified, accomplished, successful, competent and true leaders (not yes men) to come work here. I am staying far far away from this place. Been there done that...no thanks!!
 






anonymous said:
Looks like they're starting to set up interviews. Any updates on benefits?
Click to expand...

Yes, on top of the regular holidays you get 6 weeks vaca, 10 personal days, and the week between Xmas and New Years. 50k signing bonus. Medical and dental with NO copays or co-insurance. 401K matches you $2 for every $1 you put in. Starting salary is 120k with 70k bonus at target.
 






anonymous said:
research.... per financials

1/2 billion in the hole
FDA approval planned for 3.2017 assume delay
Forteo goes generic 2018
Radius price point...?
financials need to be greater than marginally profitable to maintain viability past 2018 and feed R&D for pipeline or look for acquisition.
Medicare pushing out of pocket cost to patients (not surprised if criteria is failure first prior to more expensive drug) as always in our industry.
bottom line you have to take risk to reap benefits or learn from failure to grow stronger....

Best of Luck ..
Click to expand...


Funny that nobody mentioned most important thing....new Amgen drug will most likely be approved in July. It will take over the market leaving this company done. This is a very short lived opportunity, thus why they are having trouble attracting talented sales leadership.
 






The plan with this outfit is to contract like crazy. However, Amgen will likely just do the same. So at best, it's some small time outfit vs a behemoth. With regard to sales leadership and particularly the payer team, there just isn't much great experience here. It's largely a group of people who were on the verge of being pushed out of previous companies. In fairness, Radius just couldn't get the best because the base salaries were relatively low and the options were mostly at about 10k shares or less. Radius has an ok product, but at the end of the day, they just don't have the commercial folks and overall firepower to match with the big boys.
 












Top Bottom
Back
Quote